Contineum Therapeutics, Inc. Cash Flow Statement
CTNM|1 years of annual SEC 10-K data (FY2024-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
Contineum Therapeutics, Inc. used $33M in operating cash flow and negative free cash flow of $33M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.08 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 |
|---|---|
| Net Income | -$42.3M |
| Depreciation & Amortization | $258.0K |
| Operating Cash Flow | -$32.8M |
| Capital Expenditures | $514.0K |
| Free Cash Flow | -$33.4M |
| Share Buybacks | $0 |